Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

NVS-CRF38, a new CRF1 receptor antagonist, described by Novartis

March 18, 2014

Novel, selective 5-HT5A receptor antagonist as a potential treatment for schizophrenia

March 18, 2014

A first-in-class melanocortin MC4 receptor agonist for the treatment of sexual dysfunction

March 18, 2014

LUTE and VERSE study data show efficacy for lebrikizumab in uncontrolled asthma

March 18, 2014

TK-001, TK-002 and TK-003 to be outlicensed after phase Ib

March 18, 2014

Cleave Biosciences presents new lead compound CB-5083 for tumors

March 18, 2014

Novel spirocyclic diamine derivatives with activity in animal models of CKD

March 17, 2014

GLPG-0187 shows a favorable toxicity profile in phase I trials in patients with solid tumors

March 17, 2014

Potent, pangenomic activity for ABT-493 and ABT-530 reported

March 17, 2014

Dose-related efficacy seen with house dust mite allergy immunotherapy tablet MK-8237

March 17, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...